The pay of 23 pharmaceutical companies was announced, with Murray the highest

of the listed pharmaceutical enterprises, the chairman of the highest 17.32 million, the employee per capita maximum of nearly 350,000▍10 billion revenue pharmaceutical enterprises, employee compensation out Recently, listed pharmaceutical companies have disclosed the annual report, according to the annual report of listed companies, Milnet combed out the 10 billion revenue pharmaceutical enterprises compensation information.meters net data show that a total of 23 pharmaceutical enterprises per capita salary of more than 100,000, 10 companies more than 150,000, of which, Meirui Medical, China Pharmaceuticals shares, Tiansli ranked in the top three, respectively, reached 3495 million yuan, 2238 million yuan and 1948 million yuan, Meirui Medical with a gap of 120,000, the second national pharmaceutical shares far behind.In terms of executive pay, the chairman of 13 pharmaceutical companies is paid more than $1m, and the chairman of Murray Healthcare and Fosun Pharma is paid more than $10m. The general managers of 18 pharmaceutical companies were paid more than 1 million yuan, and Meirui Medical remained the first, paying the general manager up to 16.6391 million yuan, twice the salary of the second Fosun Pharmaceuticals general manager.In terms of the number of employees, Baiyunshan, Fosun Pharma and Shanghai Pharma all have a large workforce, of which Shanghai Pharma is the largest employer, with a total of 47,590 employees.It can be seen that, whether for executives or ordinary employees, Murray Medical and Fosun Pharma pay enough generous wages, can be described as the "best employer."▍ Fosun Pharma: High executive pay, high proportion of research and developmentIt is understood that Fosun Pharma is mainly to drug research and development and manufacturing as the core, at the same time in the pharmaceutical circulation, medical services, medical diagnostics and medical devices and other fields have a high market position. The company focuses on innovation research and development, has a state-level enterprise technology center, and in Shanghai, Chongqing, the United States set up an international research and development team.Fosun Pharma's 2018 Annual Report shows that the company's pharmaceutical business invested RMB2.25 billion in research and development during the reporting period, an increase of RMB970 million, or 76.49 percent, over 2017, accounting for 12 percent of the pharmaceutical business's revenue. The increase in research and development investment was mainly due to increased investment in bio-innovative and biosynthic drugs, small-molecule innovative drugs, centralized investment in consistent evaluation, and increased investment in research and development of innovative incubation platforms during the reporting period.High executive pay and high share of research and development are common features of such research and development companies.Earlier, Endpoints News, a well-known U.S. pharmaceutical media, released the "2018 CEO Compensation list of large pharmaceutical companies", a number of listed companies CEO compensation announced, The State of Peresy's Oreqiang with 188 million yuan in the second place.Such research and development companies must attract high-end research and development talent through first-class compensation, so the overall pay level is relatively high, it is also expected.▍ Pharmaceutical Industry: Before maintaining a steady growth rate of 7
-8%
overall, Corey International released a report on trends and compensation in the healthcare industry, which showed that overall industry pay remained stable at around 7-8% growth from 2018 to 2019.Among them, job changes between similar enterprises remain at 10 to 20% of the salary increase, large foreign enterprises to domestic innovation companies or cross-industry transformation increases in 20-30%.In addition, Aon has released the 2018 Chinese Capital Insights and Trends Report, in which the average employee compensation of Chinese companies grew by 6.4% in 2018, and GDP and compensation growth have remained relatively stable for the last five years.The figure is expected to rise slightly to 6.5 per cent in 2019, with the three sectors with the highest pay rises: real estate, local medicine and high technology, at 8.9 per cent, 7.7 per cent and 7.5 per cent respectively.All along, the restrictions faced by pharmaceutical representatives are endless: the pharmaceutical representative filing system is about to land, 4 plus 7 crowding out the marketing costs of pharmaceutical companies, compliance requirements are getting higher and higher ... It seems that the medical representatives are going to be in a desperate situation.But it is clear that the overall pay level and digital increases are not so bad - at this point, how to find their core competitiveness, in an increasingly competitive environment to retain themselves, become a problem for every drug generation to consider.At the 35th China Pharmaceutical Industry Development Forum, Saibai Blue learned that with the development of innovative drugs strongly encouraged by the state, the promotion of innovative products is the key direction that the pharmaceutical generation should develop.To promote the clinical research of new drugs, so that doctors have access to more and more timely information on new drugs for the benefit of more patients, drug substitutes to maintain long-term professional vitality. (Seber Blue)